Shares of Johnson & Johnson (NYSE:JNJ) ended Tuesday session in green amid volatile trading. The shares closed up +0.43 points or 0.36% at $119.75 with 2.74 Billion shares getting traded. Post opening the session at $119.78, the shares hit an intraday low of $119.36 and an intraday high of $119.97 and the price vacillated in this range throughout the day. The company has a market cap of $328.28 Billion and the numbers of outstanding shares have been calculated to be 2.74 Billion shares.
Johnson & Johnson (JNJ) announced that it will participate in the 2016 Morgan Stanley Global Health Care Conference on Wednesday, Sept. 14, at The Grand Hyatt Hotel in New York. Alex Gorsky, Chairman and Chief Executive Officer and Dominic Caruso, Executive Vice President, Chief Financial Officer will represent the Company in a session scheduled at 9:55 a.m. (Eastern Time).
This webcast will be available to investors and other interested parties by accessing the Johnson & Johnson website at www.investor.jnj.com.
A webcast and podcast replay will be available approximately two hours after the live webcast.
Shares of Endo International plc – Ordinary Shares (NASDAQ:ENDP) ended Tuesday session in green amid volatile trading. The shares closed up +0.67 points or 3.38% at $20.49 with 222.77 million shares getting traded. Post opening the session at $19.90, the shares hit an intraday low of $19.71 and an intraday high of $20.92 and the price vacillated in this range throughout the day. The company has a market cap of $4.42 Billion and the numbers of outstanding shares have been calculated to be 222.77 million shares.
Endo International plc – Ordinary Shares (ENDP) on Aug. 18, 2016 announced that Rajiv De Silva, President and CEO, has entered into a Rule 10b5-1 stock trading plan in connection with his year-end tax planning. Under the terms of Mr. De Silva’s stock trading plan, an authorized third-party broker will sell up to 13,500 Endo shares beneficially owned by Mr. De Silva, which represents approximately 4 percent of Mr. De Silva’s total Endo stock ownership. The stock trading plan will be completed in September 2016. If all of the planned Endo share sales under Mr. De Silva’s stock trading plan are completed, Mr. De Silva will continue to beneficially own Endo shares with an aggregate market value well in excess of five times his base salary, as required by the Company’s stock ownership guidelines.